Fig. 5.

Tankyrase Inhibitor G007-LK Improves Glycemic Control in a Diabetic Mouse Model. a Tankyrase inhibitor G007-LK lowers blood glucose in db/db mice. The db/db mice were separated into four groups and i.p.-injected with vehicle (PBS), metformin (50 mg/kg), G007-LK (30 mg/kg) or the combination of metformin plus G007-LK daily for 30 days. Blood glucose levels were measured with a glucometer on the indicated days after the mice had been fasted for 18 h. b Basal plasma insulin concentrations were measured in each group at day 30. c, d Daily water consumption (c) and urine output (d) were measured after 3 weeks of treatment; data are presented as means ± SD (n = 5 independent experiments for water consumption and n = 3 for urine output). e, f Liver lipids from each group were extracted and hepatic triglyceride (e) and cholesterol (f) levels were measured. g Liver proteins from the indicated groups of db/db mice were extracted, and phosphorylation levels of AMPK and LKB1 were examined by western blotting. h, i Liver mRNAs from each group were extracted, and relative expression of PDK1 (h) and FAS (i) were determined by qPCR; transcript levels were determined relative to mRNA levels and normalized. The results represent the means ± SD (n = 3 independent experiments). Statistical significance was determined by a two-tailed, unpaired Student’s t-test. *P < 0.05; **P < 0.01; ***P < 0.001